Plano, TX, May 21, 2013 –(PR.com)– Dr. Samuel Lam, a double board-certified facial plastic surgeon in Dallas, Texas, and owner of Lam Facial Plastics, is pleased to announce that he is one of the first physicians in the United States to offer the revolutionary new miraDry procedure to treat excessive underarm sweating. The procedure utilizes…
Dallas, TX, September 24, 2012 –(PR.com)– Dr. Samuel Lam, M.D., F.A.C.S., a world renowned, board-certified hair restoration surgeon in Dallas, Texas and founder of the Lam Institute for Hair Restoration, is pleased to announce that he is now utilizing the state-of-the-art ARTAS hair restoration system to perform follicular unit extraction (FUE) hair transplant procedures. The…
Dallas, TX, November 06, 2012 –(PR.com)– Dr. Samuel Lam, M.D., F.A.C.S., a board-certified Dallas hair transplant surgeon and the Founder and Director of the Lam Institute for Hair Restoration in Plano, Texas, is pleased to announce that Ms. Emina Karamanovski has joined the practice as a member of his FUE hair transplant team. Ms. Karamanovski…
Although effective therapy for tuberculosis is available, TB continues to cause significant problems worldwide, and rates of multi-drug resistant (MDR) TB cases are on the rise. A major obstacle to the control of TB is poor adherence with lengthy (usually 6 months) and complicated treatment regimens. Incomplete TB treatment can lead to serious consequences such…
The goal of this clinical research study is to find the highest tolerable dose of immune cells called natural killer (NK) cells that can be given with chemotherapy and a stem cell transplant to patients with AML and MDS. Researchers want to learn if adding NK cells will help make the stem cell transplant more…
Cross-over, tolerability study with healthy patients taking Zavesca in combination with Florastor. Forty-two patients will be randomized to one of two treatment sequences of Zavesca with Florastor and Zavesca with Placebo of Florastor. Gastrointestinal tolerability and pK endpoints, demographic, laboratory and safety testing, and AEs and SAEs will be collected throughout the seventy-four day study.…
PRIMARY OBJECTIVES: I. To determine the safety and tolerability of XL184 (cabozantinib-s-malate) as a single agent in solid tumor patients with human immunodeficiency virus (HIV) infection and to determine the maximal tolerated dose (MTD) in this patient population. SECONDARY OBJECTIVES: I. To investigate possible pharmacokinetic interactions between cabozantinib and antiretroviral therapy in persons with HIV…
